Patent application number | Description | Published |
20100210038 | DRY REAGENT PARTICLE ASSAY AND DEVICE HAVING MULTIPLE TEST ZONES AND METHOD THEREFOR - The present invention relates to a dry reagent assay device having at least one test zone and at least one reference zone, which provides an internal mechanism for assuring correct and reliable assay procedures and reagent qualities. In one embodiment, the present invention relates to an assay device having, at least one test zone for detecting at least one analyte in a sample by reacting the sample with a labeled indicator reagent, and a reference zone for receiving, unreacted labeled indicator reagent. | 08-19-2010 |
20110091357 | ANALYTICAL SYSTEMS, DEVICES, AND CARTRIDGES THEREFOR - Described here are systems, devices, cartridges, methods, and kits for detecting or quantifying at least two different analytes using at least two different techniques, in a single sample. The cartridges typically comprise at least two test sites and the location of at least one test site is not dependent on a corresponding measurement device. The systems generally comprise a device, memory, and a processing module. The device comprises a light source, an array detector, and a port configured to accept at least a portion of a cartridge. The processing module is configured to perform an image analysis of the cartridge. The methods comprise the steps of acquiring calibration information, acquiring an image of the cartridge, performing an image analysis, and cycling through specific detection or quantification techniques corresponding to the techniques required by the test sites. Computer readable media are also described. | 04-21-2011 |
Patent application number | Description | Published |
20090093533 | COMPOUNDS AND METHODS FOR INHIBITING HEPATITIS C VIRAL REPLICATION - Macrocyclic compounds having the structures described herein are useful for inhibiting replication of the hepatitis C virus (HCV). In preferred embodiments, the compounds are active against both the NS3 protease and the NS3 helicase of HCV. | 04-09-2009 |
20090131312 | Non-natural chemokine receptor ligands and methods of use thereof - The present invention provides non-natural CXCR3 ligands comprising the N-loop region of the iTAC and polynucleotide encoding such non-natural CXCR3 ligands. The invention additionally provides methods of treating fÊbrotic disorders, angiogenic disorders, and cancer. The methods generally involve administering to an individual in need thereof an effective amount of a non-natural CXCR3 ligand of the invention. | 05-21-2009 |
20090176732 | PROTECTED NUCLEOTIDE ANALOGS - Disclosed herein are nucleotide analogs with one or more protecting groups, methods of synthesizing nucleotide analogs with one or more protecting groups and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the nucleotide analogs with one or more protecting groups. | 07-09-2009 |
20100240604 | PROTECTED NUCLEOTIDE ANALOGS - Disclosed herein are nucleotide analogs with protected phosphates, methods of synthesizing nucleotide analogs with protected phosphates and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the nucleotide analogs with protected phosphates. | 09-23-2010 |
20100249068 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS - Disclosed herein are nucleotide analogs with protected phosphates, methods of synthesizing nucleotide analogs with protected phosphates and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the nucleotide analogs with protected phosphates. | 09-30-2010 |
20100331397 | 2-5A ANALOGS AND THEIR METHODS OF USE - Disclosed herein are compounds that activate RNaseL, methods of synthesizing compounds that activate RNaseL and the use of compounds that activate RNaseL for treating and/or ameliorating a disease or a condition, such as a viral infection, a bacterial infection, cancer and/or parasitic disease. | 12-30-2010 |
20120070411 | SUBSTITUTED NUCLEOTIDE ANALOGS - Disclosed herein are phosphoroamidate nucleotide analogs, methods of synthesizing phosphoroamidate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphoroamidate nucleotide analogs. | 03-22-2012 |
Patent application number | Description | Published |
20090148407 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication - The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 06-11-2009 |
20090169510 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 07-02-2009 |
20120208995 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 08-16-2012 |